#1383

Is More Always Better? Evaluating the Addition of TRUS Biopsy to Targeted and Systematic Fusion Prostate Biopsy

C. Huang¹, W. Kuo¹, C. Yu¹

¹Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

Introduction:

Targeted and systematic fusion prostate biopsy has become increasingly popular due to its superior detection of clinically significant prostate cancer (csPCa) compared to conventional TRUS-guided biopsy. This study investigates whether adding a conventional TRUS biopsy to targeted and systematic fusion biopsy further improves the csPCa detection rate.

Material and methods:

In 2024, a total of 153 patients at our institution underwent multiparametric MRI (mpMRI), followed by targeted and systematic fusion prostate biopsy. All mpMRIs were performed using a single 3T scanner and interpreted by one experienced radiologist. Subsequently, all patients also received an additional conventional TRUS-guided biopsy. We compared the detection and upgrade rates between targeted/systematic fusion biopsy alone and the combined approach with added TRUS biopsy.

Results:

Among the 153 patients, 18 had cancer detected only through conventional TRUS biopsy. However, these cases did not contribute to an increased detection rate of clinically significant prostate cancer when compared with the results of fusion biopsy alone. Thus, the addition of TRUS biopsy provided no significant benefit in detecting or upgrading csPCa.